Minerva Neurosciences Inc (NERV)
2.37
+0.02
(+0.85%)
USD |
NASDAQ |
May 03, 16:00
2.41
+0.04
(+1.69%)
After-Hours: 20:00
Minerva Neurosciences Cash from Operations (Quarterly): -5.991M for Dec. 31, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -5.991M |
| September 30, 2023 | -4.806M |
| June 30, 2023 | -3.872M |
| March 31, 2023 | -0.1154M |
| December 31, 2022 | -4.110M |
| September 30, 2022 | -9.534M |
| June 30, 2022 | -5.193M |
| March 31, 2022 | -5.808M |
| December 31, 2021 | -4.833M |
| September 30, 2021 | -8.627M |
| June 30, 2021 | -5.925M |
| March 31, 2021 | -5.217M |
| December 31, 2020 | -7.159M |
| September 30, 2020 | -9.872M |
| June 30, 2020 | -7.589M |
| March 31, 2020 | -9.202M |
| December 31, 2019 | -14.18M |
| September 30, 2019 | -9.521M |
| June 30, 2019 | -10.13M |
| March 31, 2019 | -9.601M |
| December 31, 2018 | -9.800M |
| September 30, 2018 | -9.985M |
| Date | Value |
|---|---|
| June 30, 2018 | -11.23M |
| March 31, 2018 | -10.93M |
| December 31, 2017 | -8.912M |
| September 30, 2017 | 24.89M |
| June 30, 2017 | -6.844M |
| March 31, 2017 | -6.045M |
| December 31, 2016 | -8.928M |
| September 30, 2016 | -4.656M |
| June 30, 2016 | -6.055M |
| March 31, 2016 | -6.049M |
| December 31, 2015 | -6.603M |
| September 30, 2015 | -5.727M |
| June 30, 2015 | -7.031M |
| March 31, 2015 | -4.909M |
| December 31, 2014 | -5.017M |
| September 30, 2014 | -27.16M |
| June 30, 2014 | -2.544M |
| March 31, 2014 | -1.240M |
| December 31, 2013 | -1.210M |
| September 30, 2013 | -0.3817M |
| June 30, 2013 | -0.3894M |
| March 31, 2013 | -0.1789M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-14.18M
Minimum
Dec 2019
-0.1154M
Maximum
Mar 2023
-6.931M
Average
-5.991M
Median
Dec 2023
Cash from Operations (Quarterly) Benchmarks
| Viking Therapeutics Inc | -6.134M |
| Janux Therapeutics Inc | -9.901M |
| ACADIA Pharmaceuticals Inc | 85.39M |
| Karyopharm Therapeutics Inc | -18.58M |
| Calidi Biotherapeutics Inc | -- |
Cash from Operations (Quarterly) Related Metrics
| Free Cash Flow | -14.78M |
| Free Cash Flow Per Share (Quarterly) | -0.7904 |
| Free Cash Flow Yield | -95.97% |